Moderna Inc.’s vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday. “The vaccine is being finished … it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,” Bancel said at the World Economic Forum’s virtual Davos Agenda conference. Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. Bancel said the best case scenario was the combined COVID-19/flu vaccine would be available by the fall of 2023, at least in some countries. “Our goal is to be able to have a single annual booster so that we don’t have compliance issues where people …